Wellvii entered into a strategic partnership with B-Secur to combine at-home monitoring technology and biosensing. Palm Beach Gardens, Florida–based Wellvii offers an FDA-cleared blood pressure technology. Its solution measures blood pressure from the finger, replacing the traditional noninvasive blood pressure (NIBP) arm cuff.
B-Secur, a U.K.-based company, develops advanced biosensing technology with AI-powered electrocardiogram (ECG) solutions. Its proprietary signal processing platform delivers clinical-grade ECG data and enables faster, more confident diagnoses.
Related: Vitalograph acquires respiratory diagnostics company Morgan Scientific
The collaboration between the two companies brings B-Secur’s single-lead ECG into the Wellvi BP Go. The companies claim it could revolutionize the at-home blood pressure and heart health monitoring market.
Wellvi and B-Secur say their BP Go Rhythm BP/ECG device can offer more convenience, comfort and portability than existing devices. The companies call it a potential game-changer for ambulatory, remote patient monitoring and home monitoring. It features Bluetooth and cellular IoT connectivity for seamless data sharing, enhancing patient care around the world.
“The BP Go Rhythm puts cardiac health directly into the hands of patients with a level of comfort, portability, and connectivity that surpasses anything currently available,” said Mark Khachaturian, Wellvii CEO.
Brian Pitstick, chief commercial officer at B-Secur, added: “This partnership represents a significant step forward in delivering advanced heart health solutions to a broader audience. By combining our FDA-cleared ECG technology HeartKey with Wellvii’s innovative BP Go, we’re enabling better, more accessible cardiac monitoring for consumers and health management professionals alike.”
